Citations

Clear

48 citation(s) found for "Kelly, Kara M".

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials
Renfro, Lindsay A., Wu, Yue, Marcotte, Erin, Trippett, T, Horton, Terzah, Keller, Frank G., Forlenza, Chris, Schwartz, Cindy, Kelly, Kara M., Cole, Peter D., Castellino, Sharon M., Kahn, Justine M., Marcotte, Erin L. , Heneghan, Mallorie B. , Crisler, Katia M. , Trippett, Tanya, Horton, Terzah M. , Hoppe, Bradford S. , Keller, Frank G. , Schwartz, Cindy L. , Kelly, Kara M. , Castellino, Sharon M. , Kahn, Justine M

Mayo Clinic

Pediatric Blood & Cancer | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/1545-5017.70522 | PMID 42496647 Get It

ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and Hispanic (vs. non‐Hispanic White [NHW]) patients experienced higher post‐relapse mortality. It is unknown whether post‐relapse disparities persist when second‐line treatment is delivered in a cooperative group trial setting. We examined overall survival (OS) by race and ethnicity in CAYAs enrolled in COG trials for relapsed/refractory (r/r) cHL. Methods A pooled analysis of individual‐level data from CAYAs (≤ 29 years) receiving therapy for r/r cHL on COG clinical trials (2001–2016) was conducted. The Kaplan–Meier method estimated 3‐year OS by racial and ethnic groups. Cox regression models examined associations of race and ethnicity and OS, adjusted for age, insurance, first versus ≥2 relapse, and time from initial diagnosis to relapse trial enrollment. Results Among 175 CAYAs treated on COG trials for r/r cHL (5.7% Asian or Pacific Islander, 14.9% Hispanic, 14.3% NHB, 61.7% NHW, 3.4% other), at median follow‐up of 4.9 years, 3‐year OS was 82.1% (95% confidence interval [CI], 75.3%–87.1%) and did not differ by race and ethnicity ( p = 0.36). In multivariable analyses, shorter time from diagnosis to relapse trial enrollment ( p = 0.01) and ≥2 relapses (vs. first, p = 0.004) conferred worse OS, with no significant effect of race and ethnicity ( p = 0.43). Conclusion Post‐relapse survival did not differ by race and ethnicity among CAYAs enrolled in COG trials for r/r cHL, suggesting access to clinical trials may mitigate OS disparities.
Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group ( COG ) AHOD1331
Casey, Dana L. , Renfro, Lindsay A., Wu, Yue , McCarten, Kathleen, Pei, Qinglin , Milgrom, Sarah A., Cho, Steve, Keller, Frank G., Punnett, Angela, Kelly, Kara M., Castellino, Sharon M., Hoppe, Bradford S , Casey, Dana L , McCarten, Kathleen M. , Belsky, Jennifer A. , Keller, Frank G. , Punnett, Angela , Hodgson, David , Hoppe, Bradford S. , Kelly, Kara M. , Castellino, Sharon M.

Mayo Clinic

British Journal of Haematology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70625 | PMID 42419755 Get It

Summary Outcomes for high‐risk paediatric classic Hodgkin lymphoma (cHL) improved with the addition of brentuximab vedotin (Bv) to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC) chemotherapy. We evaluated the prognostic implications of distant extra‐nodal sites contributing to stage IV disease. On AHOD1331 (NCT02166463), patients aged 2–21 years with high‐risk cHL (stage IIB with bulk/IIIB/IVA/IVB) were randomized to 5 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE‐PC) versus Bv‐AVEPC. Patients with stage IV disease, determined by protocol‐defined and centrally reviewed Positron Emission Tomography ‐ Computed Tomography (PET‐CT), were identified. Baseline characteristics and progression‐free survival (PFS) were compared by pattern of stage IV involvement (lung, bone, bone marrow, multiple sites and others). A total of 340 patients (median age 15 years) with stage IV disease were included. Of these patients, 173 (51%) received ABVE‐PC and 167 (49%) Bv‐AVEPC. PFS was highest with lung‐only involvement (4‐year PFS 88.6%) and lowest with bone marrow‐only involvement (4‐year PFS 71.9%). Compared to ABVE‐PC, Bv‐AVEPC improved PFS among all stage IV patients (hazard ratio [HR] 0.53, 90% confidence interval (CI) 0.33–0.85) and in the lung‐only and bone‐only subgroups. However, no PFS benefit was observed in those with bone marrow‐only involvement. Among paediatric patients with stage IV cHL, Bv‐AVEPC improved PFS across most patterns of stage IV disease, except in those with bone marrow involvement. These results will guide efforts to improve outcomes among children with stage IV cHL.
E Lesion or Stage IV disease? An Ongoing Unsettled Issue in Pediatric Hodgkin Lymphoma
Seelisch, Jennifer , Mauz‐Körholz, Christine , Kelly, Kara M, Link, Michael P., Punnett, Angela, Stoevesandt, Dietrich, Kaste, Sue C. , McCarten, Kathleen M. , Kurch, Lars , Mauz-Koerholz, Christine , McCarten, Kathleen , Kurch, Lars , Hoppe, Bradford S , Flerlage, Jamie E , Kelly, Kara M. , Punnett, Angela , Palese, Monica , Hoppe, Bradford S. , Flerlage, Jamie E.

Mayo Clinic

Blood Advances | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026019753 | PMID 42361346 Get It

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Jegede, Opeyemi A. , Wang, Victoria, Ansell, Stephen M., Kostakoglu, Lale, Steidl, Christian , Natkunam, Yasodha , Scott, David W., Ambinder, Richard F, David, Kevin A. , Advani, Ranjana H, Bartlett, Nancy L., Thomas, Sachdev , Cohen, Jonathon B. , Goyal, Gaurav, Mehta-Shah, Neha, Amengual, Jennifer E. , Forlenza, Christopher Jon, Cole, Peter D. , Duan, Fenghai , Kelly, Kara M, Advani, Ranjana H. , Scott, David W. , Kostakoglu, Lale , Diefenbach, Catherine S , Jagede, Opeyemi A. , Kostakoglu, Lale , Steidl, Christian , Natkunam, Yasodha , Scott, David W , Ambinder, Richard F , David, Kevin , Bartlett, Nancy L , Thomas, Sachdev P , Cohen, Jonathon B , Goyal, Guarav , Mehta-Shah, Neha , Amengual, Jennifer E , Cole, Peter D , Advani, Ranjana H , Diefenbach, Catherine , Wang, Victoria , Ansell, Stephen M. , Ambinder, Richard F. , Bartlett, Nancy L. , Robertson, Michael J. , Ibrahimi, Sami , Goyal, Gaurav , Mehta–Shah, Neha , Forlenza, Christopher J. , Kelly, Kara M , Kahl, Brad S.

Mayo Clinic

Blood | February 9, 2026 | Volume: 147 | Issue: 18 | Pages: 2041-2052

10.1182/blood.2025029546 | PMID 41662628 Get It

Abstract The phase 1/2 Intergroup study E4412 investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) combined with the CD30 targeting antibody-drug conjugate brentuximab vedotin (BV) in relapsed/refractory classic Hodgkin lymphoma. A total of 147 patients aged ≥12 years were randomized between BV/Nivo and BV/Ipi/Nivo; 132 patients were included in the primary efficacy analysis. The complete response (CR) rate, was 64.7% (52.2, 75.9) for BV/Nivo and 70.3% (57.6, 81.1) for BV/Ipi/Nivo (1-sided P = .29). The median survival follow-up was 38.0 months (interquartile range, 32.6-48.1). Progression-free survival (PFS) did not significantly differ between the 2 arms (hazard ratio [HR], 0.78, confidence interval [CI], 0.39-1.57; 1-sided P = .24). Treatment-related grade 3+ toxicities in the adult cohort, excluding rash, were similar between both arms (38.5% BV/Nivo and 39.3% BV/Ipi/Nivo); there was a higher frequency of grade 3 rash with BV/Ipi/Nivo (24.6%) compared with BV/Nivo (9.2%). We compared PFS by stem cell transplantation (SCT) status in a planned before hoc comparison; 58 patients received SCT, and 36-month PFS (from SCT) was >90% for both arms. Sixty-six patients were progression free after the first scan and did not undergo SCT. The 36-month PFS was 73.0% (54.5, 85.0) for BV/Ipi/Nivo compared with 45.8% (26.3, 63.4) for BV/Nivo (HR, 0.45; CI, 0.19-1.08; 1-sided P = .03). The study did not meet its primary end point of superior CR rate for the triplet, but it supports the use of checkpoint antibody-drug conjugate induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT with the triplet of BV/Ipi/Nivo. This trial was registered at www.clinicaltrials.gov as NCT01896999.
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60

10.6004/jnccn.2026.0006 | PMID 41671432 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
Prognostic role of PET / CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International
Gowdy, S. Claire , Flerlage, Jamie E. , Palese, Monica , Castellino, Sharon M., Cho, Steve , Dieckmann, Karin, Hoppe, Bradford S. , Howard, Scott, Kelly, Kara M., Kurch, Lars , Lai, Hollie , Lopci, Egesta, Lucas, John T., Mauz‐Körholz, Christine, McCarten, Kathleen M. , Pandit‐Taskar, Neeta, Steglich, Jonas , Stoevesandt, Dietrich, Voss, Stephan D. , Milgrom, Sarah A. , Lucas, John T. , Gowdy, Claire , Hoppe, Bradford S , Stoevesandt, Dietrich , Flerlage, Jamie E , Seelisch, Jennifer , Bradshaw, Tyler , Castellino, Sharon M. , Dieckmann, Karin, Kelly, Kara M. , Lucas, John T., Mauz‐Körholz, Christine , Pandit-Taskar, Neeta D. , Schöder, Heiko

Mayo Clinic

British Journal of Haematology | January 15, 2026 | Volume: 208 | Issue: 4 | Pages: 1185-1195

10.1111/bjh.70329 | PMID 41535222 Get It

Summary In adults with classic Hodgkin lymphoma (cHL), metabolic tumour volume (MTV) is valuable for risk stratification. This systematic review explored the role of volumetric parameters in children, adolescents and young adults (CAYA) with cHL. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) method. Five databases were searched on 16 October 2024. Eligible studies were peer‐reviewed manuscripts, written in English, published since database inception that included patients ≤21 years of age with a diagnosis of cHL treated with chemotherapy ± radiotherapy with a baseline 18 F‐Fluorodeoxyglucose (F‐FDG) PET/CT scan for MTV quantification. The search strategy identified 3669 studies, of which 35 were eligible for inclusion. Fifteen studies (43%) evaluated a cohort exclusively ≤21 years of age. All eight studies that explored the association of baseline PET parameters with known risk factors identified a significant correlation. Nine of 12 papers (75%) demonstrated a statistically significant correlation with disease response to therapy on PET/CT. Fifteen of 20 papers (75%) demonstrated an independent statistically significant correlation with clinical outcomes. In the CAYAHL population, volumetric PET parameters are valuable for risk stratification despite heterogeneity in results. Future harmonization of the segmentation approach will facilitate incorporation of MTV into clinical practice.
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826
Castellino, Sharon M., Li, H., Herrera, Alex F. , LeBlanc, Michael, Parsons, SK, Unger, Joseph M., Punnett, Angela , Hodgson, David, Keller, FG, Drachtman, Richard A. , Lamble, Adam J. , Doan, Andrew , Rutherford, Sarah C. , Little, Richard F. , Song, Joo Y., Smith, Sonali M. , Friedberg, Jonathan W. , Kelly, Kara M., Unger, Joseph M. , Castellino, Sharon M. , Parsons, Susan K. , Hodgson, David , Keller, Frank G. , Castellino, Sharon , Li, Hongli , K Parsons, Susan , Unger, Joseph M , Hodgson, David , Keller, Frank G , Lamble, Adam , Doan, Andrew , Rutherford, Sarah C , Evens, Andrew M , Little, Richard F , Smith, Malcolm A , Hoppe, Bradford S , Song, Joo Y , Kelly, Kara M , LeBlanc, Michael L., Forlenza, Christopher J. , Evens, Andrew M. , Smith, Malcolm A. , Hoppe, Bradford S. , Kelly, Kara M.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2026 | Volume: 44 | Issue: 6 | Pages: 449-454

10.1200/jco-25-00203 | PMID 41512237 Get It

We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
Predicted Breast Cancer Risk after Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Analysis of a Multi-Institutional Children’s Oncology Group Trial
Milgrom, Sarah A. , Dama, Hitesh, Renfro, Lindsay A. , Wu, Yue , Meyer, Ilan H. , Jeeva, Meenakshi , Punnett, Angela , Charpentier, A-M, Keller, Frank G. , Kelly, Kara M. , Paganetti, Harald , Meyer, I, Parsons, Susan K. , Charpentier, A-M, Lo, Acy , Vega, Raymond B. Mailhot , Hoppe, Bradford S. , Castellino, Sharon M. , Hodgson, David

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812961 Get It